GlassScriptPhysician profile
Ludwig V Cavaliere
NPI 1952300469
$1,114.90
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $427 · 2021: $477.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $154.41 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $135.49 | 2021 | |
| Allergan, INC. | $124.01 | 2020 | |
| Abbvie INC. | $113.32 | 2021 | |
| Vifor Pharma, INC. | $107.18 | 2019-2021 | |
| Akebia Therapeutics INC | $99.25 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $71.76 | 2019-2021 | |
| Daiichi Sankyo INC. | $70.28 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $43.73 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $38.44 | 2021 | |
| Horizon Therapeutics Plc | $37.10 | 2019 | |
| Opko Pharmaceuticals, LLC | $23.64 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.26 | 2020 | |
| Amgen INC. | $17.59 | 2020 | |
| Mallinckrodt Hospital Products INC. | $16.17 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $16.04 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.77 | 2019 | |
| Travere Therapeutics, INC. | $11.46 | 2020-2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ludwig Cavaliere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.